Privately held Aicuris reported Phase 3 success for pritelivir, an oral antiviral for refractory herpes infections, announcing that patients on the drug outperformed standard‑of‑care in the trial. The company plans a U.S. regulatory submission in 2026 based on the dataset. The Phase 3 readout targets immunocompromised populations with unmet antiviral needs; Aicuris’ release and follow‑up press attention signaled potential label expansion and a new oral option against resistant HSV. Coverage appeared in multiple outlets and was reflected in company statements about next‑step regulatory strategy.